OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Executive Summary
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.
You may also be interested in...
Perrigo Gains US Approval For OTC Guaifenesin/Pseudoephedrine Manufacturing
Predominant US OTC private label/store brand provider plans commercialize products in second half. Firm has yet to set date to release 2021 full-year and fourth-quarter results.
Aleve Has A ‘Headache’ For Proprietary Brand And As First Indication On Labeled Uses List
US FDA approves Bayer HealthCare's supplemental NDA for adding Aleve Headache Pain proprietary name to use with the brand’s regular strength formulation, naproxen 220 mg. The approval also allows moving headache to top of indications list.
Lumify A Clear Bausch Consumer Sales Driver But COVID-19 Clouds Q1 Results And Guidance
Bausch reported global sales of Lumify eye drops, PreserVision supplements and other consumer health products up 8.9% to $353m. However, its net loss grew to $152m from $52m in the year-ago period on a $65m dent in its income due to mass postponements of ocular and dermatologic surgeries.